Drug intelligence / Profile preview

OmepraCare

Development stage: Unknown
Lead developer: Aytu BioPharma
Modality: Small Molecules
Administration: Oral

Overview

OmepraCare is an over-the-counter oral **omeprazole** product developed and commercialized by Innovus Pharmaceuticals for the treatment of frequent heartburn occurring 2 or more days per week. It is a **small-molecule proton pump inhibitor** formulated as 20 mg tablets and delayed-release capsules marketed as OmepraCare DR, and was launched under FDA-approved ANDA 207891. Omeprazole suppresses gastric acid secretion by inhibiting the gastric parietal cell **H+/K+-ATPase proton pump**, providing once-daily, 24-hour acid reduction and positioning the product as a branded OTC competitor to Prilosec OTC.

Brand names: OmepraCareOmepraCare DR
Other names: omeprazole

Targets

THBS1 (Thrombospondin-1)ATP4A (Potassium–transporting ATPase alpha chain 1)COL1 (Collagen type I)BB-031 (Von Willebrand factor)DCN (Decorin)

Beyond the preview

Go deeper on OmepraCare.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OmepraCare.

Explore the full profile